Redeye: FluoGuide Q4 2024 - Edging closer to clinical results
Redeye comments on FluoGuide’s Q4 2024 report. The company is approaching the interim readout of its phase II trial in HNC (H2 2025e), which we judge could pave the way for initiating pivotal trials. Further, we judge Fluoguide’s business development prospects remain healthy. We update our estimates and valuation.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/